Prostate cancer
The chart below reflects the Cancer Treatment Centers of America® (CTCA) and SEER survival rates for prostate cancer patients with distant (metastatic) disease who were diagnosed between 2000 and 2015. It includes estimates of the percentage of prostate cancer patients with distant (metastatic) disease who survived for six months to five years after the initial diagnosis, as recorded in the CTCA® and SEER databases.
- This analysis included prostate cancer patients from CTCA who had primary tumor site (as coded by ICD-O-2 (1973+)) of C619, were diagnosed from 2000 to 2015 (including 2000 and 2015) and received at least part of their initial course of treatment at CTCA. All patients included in the analysis were considered analytic patients by CTCA.
- Prostate cancer patients with distant (metastatic) disease from the SEER database and prostate cancer patients with distant (metastatic) disease from the CTCA database were included in the analysis. In addition, the analysis excluded patients whose medical records were missing any of the following information:
- SEER Summary Stages
- Primary tumor sites
- Cancer histologic types
- Date of initial diagnosis
- Age at initial diagnosis
- Gender and race
*The SEER data represent national results over a large number of institutions and have been included for illustrative purposes. They are not intended to represent a controlled study and/or a perfect analysis of the CTCA data because of variability in the sample sizes of the two databases, the clinical condition(s) of the patients treated and other factors.
